What is CLLS's current stock price?

CLLS (Cellectis S.A.) is currently trading at $3.73 with a market cap of $374.0M.

What sector is Cellectis S.A. in?

Cellectis S.A. (CLLS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CLLS a good stock to buy?

Analysts have a Buy consensus on CLLS with a price target of $6.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CLLS Cellectis S.A.

Healthcare

$3.73+0.00%OpenMarket Cap: $374.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.35

P/S

4.02

EV/EBITDA

-7.72

DCF Value

$-5.40

FCF Yield

-14.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.9%

Operating Margin

-69.2%

Net Margin

-98.7%

ROE

-80.6%

ROA

-23.3%

ROIC

-26.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$5.8M	$-17.8M	$—
Q4 null	$10.4M	$-26.3M	$—
FY null	$72.9M	$-67.6M	$—
Q3 null	$35.2M	$589.0K	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$4.00 - $8.00

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

CitizensMarket Outperform

2026-04-14

BarclaysOverweight

2025-10-17

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.93

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Peers